Reduction of telomeric length and c-erbB-2 gene amplification in human breast cancer, fibroadenoma, and gynecomastia. Relationship to histologic grade and clinical parameters - PubMed (original) (raw)
Reduction of telomeric length and c-erbB-2 gene amplification in human breast cancer, fibroadenoma, and gynecomastia. Relationship to histologic grade and clinical parameters
E Odagiri et al. Cancer. 1994.
Abstract
Background: Telomeric deletions contribute to genetic instability and may represent an important mechanism of carcinogenesis. Amplification of the c-erbB-2 gene has been demonstrated in breast carcinoma. The clinical significance of telomeric deletions and c-erbB-2 gene amplification therefore was studied in patients with breast disorders.
Methods: The Southern blot analysis was used to measure telomeric length as well as the c-erbB-2 gene amplification of breast carcinomas, adjacent normal breast tissues, fibroadenomas, and cases of gynecomastia.
Results: Significant reductions in telomeric length and concentration were observed in all breast tissues when compared to placental DNA. Mean telomeric lengths were lowest in carcinomas and fibroadenomas. There were no significant differences, however, in the telomeric lengths among tissues from patients with breast carcinomas, fibroadenomas, or gynecomastia. The degree of telomeric deletion correlated significantly with histologic grade and was most notable in Grade 3 (scirrhous) breast carcinoma. The extent of telomeric deletion reflects the histologic aggressiveness of breast carcinoma, and telomeric reduction already can be seen in the adjacent normal breast tissues from patients with breast cancer. c-erbB-2 gene amplification was observed in 26.8% of the patients with breast carcinoma. c-erbB-2 gene amplification was not observed, however, in patients with fibroadenomas or gynecomastia. The degree of telomeric deletion did not correlate with c-erbB-2 gene amplification, tumor size, clinical stage, steroid receptors, or prognosis. Telomeric length was shorter in lymph node-negative tumors than in lymph node-positive tumors.
Conclusions: These findings indicate that a shorter telomere length reflects growth advantage in breast cancer tissue, and telomeric reduction may promote cancer progression.
Similar articles
- What's new in breast cancer? Molecular perspectives of cancer development and the role of the oncogene c-erbB-2 in prognosis and disease.
Dawkins HJ, Robbins PD, Smith KL, Sarna M, Harvey JM, Sterrett GF, Papadimitriou JM. Dawkins HJ, et al. Pathol Res Pract. 1993 Dec;189(10):1233-52. doi: 10.1016/S0344-0338(11)80853-8. Pathol Res Pract. 1993. PMID: 7910395 Review. - Chromosome 11q13, c-erbB-2, and c-myc amplification in invasive breast carcinoma: clinicopathologic correlations.
Gaffey MJ, Frierson HF Jr, Williams ME. Gaffey MJ, et al. Mod Pathol. 1993 Nov;6(6):654-9. Mod Pathol. 1993. PMID: 7905628 - c-erbB-2 amplification in node-negative human breast cancer.
Ro JS, el-Naggar A, Ro JY, Blick M, Frye D, Fraschini G, Fritsche H, Hortobagyi G. Ro JS, et al. Cancer Res. 1989 Dec 15;49(24 Pt 1):6941-4. Cancer Res. 1989. PMID: 2573424 - c-erbB-2 and c-erbA-1 (ear-1) gene amplification and c-erbB-2 protein expression in Japanese breast cancers: their relationship to the histology and other disease parameters.
Uehara T, Kaneko Y, Kanda N, Yamamoto T, Higashi Y, Nomoto C, Izumo T, Takayama S, Sakurai M. Uehara T, et al. Jpn J Cancer Res. 1990 Jun-Jul;81(6-7):620-4. doi: 10.1111/j.1349-7006.1990.tb02618.x. Jpn J Cancer Res. 1990. PMID: 1976118 Free PMC article. - c-erbB-2 amplification in mammary carcinoma.
Barnes DM. Barnes DM. J Cell Biochem Suppl. 1993;17G:132-8. doi: 10.1002/jcb.240531126. J Cell Biochem Suppl. 1993. PMID: 7911860 Review.
Cited by
- Assessing cell and organ senescence biomarkers.
Bernardes de Jesus B, Blasco MA. Bernardes de Jesus B, et al. Circ Res. 2012 Jun 22;111(1):97-109. doi: 10.1161/CIRCRESAHA.111.247866. Circ Res. 2012. PMID: 22723221 Free PMC article. Review. - Selected telomere length changes and aberrant three-dimensional nuclear telomere organization during fast-onset mouse plasmacytomas.
Kuzyk A, Mai S. Kuzyk A, et al. Neoplasia. 2012 Apr;14(4):344-51. doi: 10.1593/neo.12446. Neoplasia. 2012. PMID: 22577349 Free PMC article. - Telomeres and Age-Related Diseases.
Gruber HJ, Semeraro MD, Renner W, Herrmann M. Gruber HJ, et al. Biomedicines. 2021 Sep 27;9(10):1335. doi: 10.3390/biomedicines9101335. Biomedicines. 2021. PMID: 34680452 Free PMC article. Review. - Potential clinical role of telomere length in human glioblastoma.
La Torre D, Aguennouz M, Conti A, Giusa M, Raffa G, Abbritti RV, Germano' A, Angileri FF. La Torre D, et al. Transl Med UniSa. 2011 Oct 17;1:243-70. Print 2011 Sep. Transl Med UniSa. 2011. PMID: 23905037 Free PMC article. - Telomere maintenance in laser capture microdissection-purified Barrett's adenocarcinoma cells and effect of telomerase inhibition in vivo.
Shammas MA, Qazi A, Batchu RB, Bertheau RC, Wong JY, Rao MY, Prasad M, Chanda D, Ponnazhagan S, Anderson KC, Steffes CP, Munshi NC, De Vivo I, Beer DG, Gryaznov S, Weaver DW, Goyal RK. Shammas MA, et al. Clin Cancer Res. 2008 Aug 1;14(15):4971-80. doi: 10.1158/1078-0432.CCR-08-0473. Clin Cancer Res. 2008. PMID: 18676772 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical
Research Materials
Miscellaneous